Literature DB >> 28965736

Second annual Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs) report: Pre-implant characteristics and outcomes.

Elizabeth D Blume1, Christina VanderPluym2, Angela Lorts3, J Timothy Baldwin4, Joseph W Rossano5, David L S Morales3, Ryan S Cantor6, Marissa A Miller4, James D St Louis7, Devin Koehl6, David L Sutcliffe8, Pirooz Eghtesady9, James K Kirklin6, David N Rosenthal10.   

Abstract

BACKGROUND: Expanded use of pediatric ventricular assist devices (VADs) has decreased mortality in children awaiting heart transplantation. Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs), a National Heart, Lung, and Blood Institute-sponsored North American database, provides a platform to understand this emerging population.
METHODS: Between September 2012 and September 2016, patients aged younger than 19 years who underwent VAD implantation were enrolled in Pedimacs. FDA approved durable devices as well as temporary support devices were included. The second annual report updates the current Pedimacs data. Patients implanted with temporary devices are included in Pedimacs and this analysis includes this group of paracorporeal continuous flow VADs.
RESULTS: Over the 4 years, 42 hospitals implanted 432 devices in 364 patients less than 19 yrs of age. Diagnoses included cardiomyopathy in 223 (61%), myocarditis in 41 (11%), and congenital heart disease in 77 (21%), of which 48 had single-ventricle physiology. At implant, 87% were at Intermacs patient profile 1 or 2. The age distribution of children (59% male) supported on VAD included 69 (19%) aged younger than 1 year, 66 (18%) aged 1 to 6 years, 56 (15%) aged 6 to 10 years, and 173 (48%) aged 11 to 19 years. Median follow-up was 2.2 months (range, 1 day to 41.5 months). Median (interquartile) age at implant was 1.7 (0.3-10.0) years for paracorporeal continuous-flow pumps (n = 60), 1.7 (0.4-5.3) years for paracorporeal pulsatile pumps (n = 105), and 15.0 (11.3-16.9) years for implantable continuous-flow pumps (n = 174). Support strategies included LVAD in 293 (80%), biventricular device in 55 (15%), and total artificial heart in 8 (2%). Nearly 50% of patients underwent transplantation within 6 months, with overall mortality of 19%. Adverse event burden continues to be high.
CONCLUSIONS: Pedimacs constitutes the largest longitudinal pediatric VAD registry. Preimplant data across centers will be helpful at creating shared protocols with which to improve outcomes. Adverse events continue to be the major challenge, especially among the young critically ill children with complex congenital disease.
Copyright © 2018 International Society for the Heart and Lung Transplantation. All rights reserved.

Entities:  

Keywords:  Pedimacs; advanced heart failure; bridge to transplant; children; mechanical support; pediatrics; ventricular assist device

Mesh:

Year:  2017        PMID: 28965736     DOI: 10.1016/j.healun.2017.06.017

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  14 in total

1.  Infant miniaturized continuous-flow pumps and permanent support in Pediatrics.

Authors:  Rachele Adorisio; Maria Grandinetti; Antonio Amodeo
Journal:  Ann Cardiothorac Surg       Date:  2021-03

2.  Paving a Road Home: Developing Education for a Pediatric Home-Going VAD Program.

Authors:  Vicky Duffy; Deipanjan Nandi; Ashley Hodge; Matt Deitemyer; Janet Simsic
Journal:  J Extra Corpor Technol       Date:  2019-12

3.  Outcomes of children with congenital heart disease implanted with ventricular assist devices: An analysis of the Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs).

Authors:  David M Peng; Devin A Koehl; Ryan S Cantor; Kristen N McMillan; Aliessa P Barnes; Patrick I McConnell; Jessica Jordan; Nicholas D Andersen; James D St Louis; Katsuhide Maeda; James K Kirklin; Steven J Kindel
Journal:  J Heart Lung Transplant       Date:  2018-10-31       Impact factor: 10.247

Review 4.  Current status and future perspectives of the PumpKIN trial.

Authors:  Iki Adachi
Journal:  Transl Pediatr       Date:  2018-04

5.  Use of advanced heart failure therapies in Duchenne muscular dystrophy.

Authors:  Carol A Wittlieb-Weber; Chet R Villa; Jennifer Conway; Matthew J Bock; Katheryn E Gambetta; Jonathan N Johnson; Ashwin K Lal; Kurt R Schumacher; Sabrina P Law; Shriprasad R Deshpande; Shawn C West; Joshua M Friedland-Little; Irene D Lytrivi; Michael A McCulloch; Ryan J Butts; David R Weber; Kenneth R Knecht
Journal:  Prog Pediatr Cardiol       Date:  2019-01-11

Review 6.  Complications in children with ventricular assist devices: systematic review and meta-analyses.

Authors:  Andrea Nicola George; Tain-Yen Hsia; Silvia Schievano; Selim Bozkurt
Journal:  Heart Fail Rev       Date:  2021-03-04       Impact factor: 4.214

7.  Psychosocial outcomes in pediatric patients with ventricular assist devices and their families: A systematic review.

Authors:  Kelly E Rea; Amanda M McCormick; Heang M Lim; Melissa K Cousino
Journal:  Pediatr Transplant       Date:  2021-03-11

8.  Integrated long-term multifunctional pediatric mechanical circulatory assist device.

Authors:  Harutyun Sarkisyan; Randy Stevens; Vakhtang Tchantchaleishvili; Joseph Rossano; Amy Throckmorton
Journal:  Artif Organs       Date:  2020-12-29       Impact factor: 2.663

9.  Cardiovascular Disease in the Young Council's Science and Clinical Education Lifelong Learning Committee: Year in Review.

Authors:  Sushma Reddy; Bradley S Marino; Carissa M Baker-Smith; Andrea Beaton; Catherine D Krawczeski; Christina Y Miyake; James F Cnota; Andrew C Glatz; Brian Feingold; Jennifer C Romano; Antonio G Cabrera; Anitha S John; Meryl S Cohen
Journal:  J Am Heart Assoc       Date:  2018-11-06       Impact factor: 5.501

Review 10.  State of the art of the Fontan strategy for treatment of univentricular heart disease.

Authors:  Jelle P G van der Ven; Eva van den Bosch; Ad J C C Bogers; Willem A Helbing
Journal:  F1000Res       Date:  2018-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.